Carboplatin plus paclitaxel to be the new standard of care for anal cancer

Non-Sponsored Content

CHEMOTHERAPY

Carboplatin plus paclitaxel to be the new standard of care for anal cancer

Medical writer: Kirsty LEE | Last updated: 10th July 2020 | In: AIDS, Chemotherapy, Gastrointestinal Cancer, HIV, Infectious Disease, Oncology

Article Keywords

5FU, anal cancer, antiretroviral therapy, carboplatin, CD4-count, cisplatin, colorectal cancer, CRC, epidermoid anal squamous carcinoma, fluorouracil, HIV, mCRC, paclitaxel, rectal cancer

The incidence of anal cancer has been increasing over the past decade, but currently still only constitutes 0.5% of all cancer diagnoses in the United States.¹ When anal cancer metastasises, the prognosis is poor, with relative 5-year survival rates of approximately 30%.² The current standard of care for metastatic anal cancer is cisplatin-based chemotherapy combined with 5-fluorouracil (5-FU).¹ However, no randomised clinical trial investigating the optimal chemotherapy regimen for this disease has been conducted.² The InterAAct trial was launched to investigate cisplatin plus FU against carboplatin plus paclitaxel in advanced anal cancers, and full results were recently published in the Journal of Clinical Oncology.²

The international, open-label, multicentre randomised phase II InterAAct trial aimed to set a standard of care for anal cancer and establish a cytotoxic backbone for future trials.² Participating patients were aged ≥18 years with histologic confirmation of locally recurrent inoperable or metastatic epidermoid anal squamous carcinoma.² HIV-positive patients were included if they were receiving highly active antiretroviral therapy and CD4 count was ≥200μ/L, or CD4 count ≤200μ/L.² Patients were allocated 1:1 to receive either cisplatin plus FU, or carboplatin plus paclitaxel. Patients were treated for 24 weeks or until disease progression, intolerable toxicity, or withdrawal of consent.²The primary endpoint was overall response rate (ORR), and secondary endpoints included progression-free survival (PFS), overall survival (OS), and assessments of adverse events (AEs).²

A total of 91 patients were recruited, and 45 assigned to carboplatin plus paclitaxel, and 46 to cisplatin plus FU.² Majority of patients had metastatic disease and were HIV negative.² ECOG PS was 0/1 in most patients. After a median follow-up of 28.6 months, ORR was 57% for cisplatin plus FU, vs 59% for carboplatin plus paclitaxel.² Median PFS was not statistically different, at 5.7 months for cisplatin plus FU, vs 8.1 months with carboplatin plus paclitaxel.² Median OS was 12.3 months for cisplatin plus FU, compared with 20 months for carboplatin plus paclitaxel, with a trend towards significant difference.²

Patients in the cisplatin plus FU arm experienced more nausea, vomiting, mucositis, and diarrhoea, while patients receiving carboplatin plus paclitaxel had more neutropenia and anaemia.² There were more serious AEs with cisplatin plus FU vs carboplatin plus paclitaxel (62% vs 36%; p=0.016).² However, as the trial aimed to set a standard of care, although no significant difference in ORRs was observed, the significantly fewer serious AEs and improved toxicity profile led to the conclusion that carboplatin plus paclitaxel should be considered the new standard of care in untreated advanced anal cancer.²

Reference

Symer MM & Yeo HL. F1000Res. 2018; 7: F1000 Faculty Rev-1572.

Rao S, et al. J Clin Oncol. 2020 Jun 12;JCO1903266.

Newsletter Sign-Up

Do you like our content? Subscribe to our non-intrusive newsletter today! We promise we won’t be spammy.

Dosing issues with DOACs in Asian real world setting

Sotorasib approved as the first targeted therapy for Lung Cancer

Sotorasib approved as the first targeted therapy for KRAS-Mutant Lung Cancer

Amivantamab in combination with Lazertinib showed efficacy in NSCLC

ASCO GI Webinar: Update on NET and HCC

23rd December 2021

Dosing issues with DOACs in Asian real world setting

22nd November 2021

Sotorasib approved as the first targeted therapy for KRAS-Mutant Lung Cancer

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).

Non-Sponsored Content